Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Oncocross.

    Client Virtual Booth

    ONCOCROSS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Oncocross
    korearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    11th, 16th floor, Saechang-ro, Mapo-gu, Seoul
    Telephone
    Telephone
    02-867-9967
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncocross.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia

    Details:

    Oncocross is developing OC514 as a drug-drug combination product designed to prevent or treat sarcopenia and other rare muscular diseases, using Oncocross’ proprietary AI platform RAPTOR AI™.


    Lead Product(s): OC514

    Therapeutic Area: Musculoskeletal Product Name: OC514

    Highest Development Status: Phase IProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 10, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncocross Launches Global Clinical Trials for AI-based Sarcopenia Treatment

    Details:

    Oncocross obtained Australia’s TGA approval on phase I IND application for OC514, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics for targeting muscular diseases including sarcopenia.


    Lead Product(s): OC514

    Therapeutic Area: Musculoskeletal Product Name: OC514

    Highest Development Status: Phase IProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 25, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search